Micropulse diode laser trabeculoplasty (MDLT): A phase II clinical study with 12 months follow-up by Fea, Antonio Maria et al.
© 2008 Fea et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2008:2(2) 247–252 247
ORIGINAL RESEARCH
Micropulse diode laser trabeculoplasty (MDLT): 
A phase II clinical study with 12 months follow-up
Antonio Maria Fea
Alex Bosone
Teresa Rolle
Beatrice Brogliatti
Federico Maria Grignolo
Istituto di Fisiopatologia Clinica, 
Clinica Oculistica dell’ Università 
di Torino, Torino, Italy
Correspondence:   Antonio Fea
Istituto di Fisiopatologia Clinica, Clinica 
Oculistica dell’ Università di Torino, 
Via Juvarra 19, 10100 Torino, Italy
Email antoniofea@interfree.it
Objective: This pilot study evaluates the pressure lowering potential of subthreshold micropulse 
diode laser trabeculoplasty (MDLT) for a clinically meaningful duration in patients with medi-
cally uncontrolled open angle glaucoma (OAG).
Design: prospective interventional case series.
Participants: Thirty-two eyes of 20 consecutive patients with uncontrolled OAG (12 bilateral 
and 8 unilateral).
Methods: Conﬂ  uent subthreshold laser applications over the inferior 180° of the anterior TM 
using an 810 nm diode laser in a micropulse operating mode. The intraocular pressure (IOP) was 
measured at baseline and at 1 hour, 1 day, 1 week, 3, 6, 9, and 12 months post-treatment. Flare 
was measured with a Kowa FM 500 ﬂ  are-meter at baseline and at 3 hours, 1 day, 1 week, and 
12 months post-treatment. After treatment, the patients were maintained on their pre-treatment 
drug regimen.
Main outcome measures: Criteria for treatment response were IOP reduction 3 mm Hg and 
IOP 21 mm Hg within the ﬁ  rst week after MDLT. Eyes not complying to the above criteria 
during the follow-up were considered treatment failure. Mean IOP change and percentage of 
IOP reduction during the follow-up were calculated.
Results: One eye was analyzed for bilateral patients. A total of 20 eyes were thus included. 
Four eyes (20%) did not respond to treatment during the ﬁ  rst week. One additional eye failed 
at the 6 month visit. The treatment was successful in 15 eyes (75%) at 12 months. The IOP was 
signiﬁ  cantly lower throughout follow-up (p  0.01). At 12 months, the mean percentage of IOP 
reduction in the 15 respondent eyes was 22.1% and 12 eyes (60%) had IOP reduction higher than 
20%. During the ﬁ  rst two postoperative days, one eye with pigmentary glaucoma experienced a 
signiﬁ  cant increase of ﬂ  are associated with an IOP spike (34 mm Hg) that was controlled with 
systemic drugs; afterwards it qualiﬁ  ed as a respondent and completed the study. No increase of 
ﬂ  are was found in any other patient. No peripheral anterior synechiae formed.
Conclusions: In this case series, MDLT was effective in reducing IOP in 75% of medically 
insufﬁ  ciently controlled OAG eyes without signiﬁ  cant complications. This justiﬁ  es randomized 
clinical studies to compare MDLT with current IOP lowering strategies.
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Introduction
Following the publication of Wise and Witter’s pilot study on 40 eyes treated with 
argon laser trabeculoplasty (ALT) in 1979 (Wise and Witter 1979), ALT became a 
commonly performed procedure for the treatment of primary open-angle glaucoma 
(POAG), exfoliation syndrome glaucoma, pigmentary glaucoma, and normal-tension 
glaucoma.
On the basis of the evidence from the Glaucoma Laser Trial Follow-up Study 
(GLTFS) (GLTRG 1995), the investigators reported that ALT is superior to 
medications as ﬁ  rst-line therapy in newly diagnosed POAG. Nevertheless, ALT has 
not become a primary treatment of choice; it has mainly been used as an adjunctive Clinical Ophthalmology 2008:2(2) 248
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therapy, reserved for patients with poorly controlled intra-
ocular pressure (IOP) under maximum tolerated medical 
therapy. While the efﬁ  cacy of ALT in reducing IOP has 
been documented, side effects are frequently encountered, 
including IOP spikes in the early post-ALT period, local 
scarring of the trabecular meshwork, onset of peripheral 
anterior synechiae, and limited IOP response to repeated 
ALT (Wise and Witter 1979; Wilensky and Weinreb 1983; 
Traverso et al 1984; Feldman et al 1991).
In 1995, Latina and Park (1995) introduced selective 
laser trabeculoplasty (SLT) and noted reduced laser collateral 
damage and fewer ALT side-effects. SLT utilizes a single 3 
ns duration pulse of a 532 nm laser with large 400 μm spot 
to selectively destroy pigmented TM cells with no damage 
to adjacent nonabsorbing cells in accordance with the prin-
ciples of selective photothermolysis (Anderson and Parrish 
1983). In several studies, SLT has produced IOP-lowering 
effects comparable with ALT (Damji et al 1999; Reno et 
al 1999; Juzych et al 2004) with a lower, but still consider-
able, post-operative inﬂ  ammation and occurrence of pres-
sure spikes, especially in eyes with heavily pigmented TM 
(Martinez-de-la-Casa et al 2004; Harasimowycz et al 2005).
Trabeculoplasty with subvisible applications (subthresh-
old) of repetitive short diode laser pulses, named micropulse 
diode laser trabeculoplasty (MDLT) to differentiate it from 
the conventional continuous wave (CW) diode laser trabecu-
loplasty (DLT) (McHugh et al 1990; Brancato et al 1991), 
was tested in a short-term prospective controlled pilot study 
in which patients with uncontrolled OAG were randomized 
to either MDLT or ALT (Ingvoldstad et al 2005). At the 
3-month follow-up visit, the IOP reduction was statistically 
signiﬁ  cant and comparable in both study arms, but, with 
MDLT, intraoperative pain, postoperative inﬂ  ammation, and 
cell/ﬂ  are reaction were negligible and signiﬁ  cantly lower 
than with ALT.
The objective of the present study was to evaluate the 
pressure lowering potential of MDLT in eyes with uncon-
trolled OAG over a longer and clinically meaningful follow-
up period of 12 months.
Materials and methods
Study design
Prospective pilot study of consecutive patients with uncon-
trolled OAG on maximal tolerated medical therapy.
Eligibility and exclusion criteria
Consecutive patients were eligible for the study if they met the 
following entry criteria: 1) an average IOP greater than 22 mm 
Hg at three pre-treatment visits in separate days within two 
weeks; and 2) a clinical history in our clinic of at least two years 
without clinically signiﬁ  cant IOP variations that could suggest a 
good compliance to medical treatment. Patients were excluded 
if they presented with: 1) evidence of glaucoma other than 
OAG (angle-closure, neovascular); 2) any previous glaucoma 
surgery (including ALT and laser iridotomy); 3) ocular condi-
tions which may require ocular surgery; and 4) severe visual 
ﬁ  eld (Humphrey) defect in both eyes according to the Hodapp 
classiﬁ  cation (Hodapp et al 1993). Ethics committee approval 
was obtained. All eligible patients entered in the study signed 
an informed consent form acknowledging their understanding 
of the goals, procedures, and risks of the study.
Subjects
Twenty out of twenty-eight consecutive patients gave their 
consent and entered the study with a total of 32 eligible eyes 
(8 unilateral and 12 bilateral). Baseline data for each patient 
included full ocular and medical history, slit lamp biomicros-
copy with gonioscopy, ﬂ  are determination using the Kowa 
FM 500 ﬂ  are-meter, pachimetry, mydriatic funduscopy, and 
visual ﬁ  eld assessment (Humphrey 24–2). At least three IOP 
measurements were taken with the Goldmann applanation 
tonometer on separate days, between 8.30 and 9.30 a.m. 
within two weeks before the treatment. IOP measurements 
were not adjusted for central corneal thickness. The median 
of the measurements was taken as the baseline IOP.
Laser technique
We did MDLT with the IRIS Medical OcuLight SLx 
810 diode laser system (IRIDEX Corporation, Mountain 
View, CA, USA), a commercially available laser device, 
FDA-cleared for various indications including retinal pho-
tocoagulation, laser trabeculoplasty, transscleral cyclopho-
tocoagulation, and other diode laser ocular treatments. The 
micropulse laser settings, largely derived from the parameters 
clinically tested in a prospective, randomized pilot study 
(Ingvoldstad et al 2005) were as follows: 200 μm spot size 
diameter, 2 W power (6.4 KW/cm2 irradiance), and 200 ms 
duration with 15% duty cycle. With these settings, a train of 
100 laser pulses with 300 μs “ON” time, each separated by 
1700 μs “OFF” time, is delivered with each 200 ms appli-
cation. Patients received a single MDLT treatment and no 
retreatment was permitted.
All MDLT procedures were performed by the ﬁ  rst author 
(AMF). After a drop of topical anesthetic (Oxybuprocaine 
0.4% with methylcellulose), the patient was seated at the slit 
lamp and a laser antireﬂ  ective coated Goldmann three-mirror Clinical Ophthalmology 2008:2(2) 249
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lens (Ocular Instruments, Bellevue, WA, USA) was placed on 
the eye to be treated. The laser was carefully focused on the 
anterior trabecular meshwork and conﬂ  uent applications were 
administered over the inferior 180°. Since no visible laser-
induced tissue change endpoint is produced at the TM with 
the above laser parameters, and due to eye movements during 
the treatment, the placement of invisible conﬂ  uent applications 
over the inferior 180 degrees relied on the surgeon’s judgment 
and skill, resulting in a variable number of conﬂ  uent and even 
overlapping spots. The total number of laser applications 
delivered to each eye was recorded after each treatment.
Post-operative follow-up
Immediately after the treatment, indomethacin 0.1% eye 
drops were administered and continued three more times 
during the ﬁ  rst day. Nonsteroidal anti-inﬂ  ammatory eye 
drops were chosen instead of steroidals due to the potential 
confounding effect of steroidal eye drops in glaucomatous 
responders. IOP was assessed in all patients 3 hours after 
the laser treatment and further monitored in case of IOP 
raised 3 mm Hg. Systemic acetazolamide (Diamox 250 mg) 
was the treatment of choice for IOP spikes in order to mini-
mize confounding long term IOP-lowering effects hiding the 
effects of the laser treatment. As soon as IOP normalized, 
acetazolamide was discontinued. All IOP measurements 
made during the treatment with acetazolamide were excluded 
from the analysis. Patients were evaluated at 1 day, 1 week, 
1 month, 3 months, 6 months, 9 months, and 12 months. 
At each visit, anterior segment examination, best corrected 
visual acuity and IOP measurements were performed. Flare 
was measured at baseline, at 3 hours, 1 day, 1 week, and 
1 year after the treatment. At the one year examination, 
gonioscopy and a visual ﬁ  eld test were performed. All the 
post-operative visits were performed by observers unaware 
of the treatment and of the patients’ clinical history (AB and 
TR). IOP was always measured between 8.30 and 9.30 am 
to minimize the effects of diurnal variations. Preoperative 
medications were maintained unchanged throughout the 
course of the study. During the ﬁ  rst post-op week, patients 
who did not achieve an IOP reduction 3 mm Hg or whose 
IOP was 21 mm Hg were considered nonresponders and 
excluded from further study follow-up to allow changes 
in their therapy, as deemed appropriate by the physician. 
Furthermore, any eye with IOP greater than 21 mm Hg or 
that did not have an IOP reduction higher than 3 mm Hg at 
any time point was considered a failure and the patient was 
excluded from further study follow-up to allow appropriate 
therapy changes.
Measures of outcome
Eyes were censored from further analysis upon nonresponse or 
failure. The mean IOP at each visit was compared using two-
tailed paired t test. The percentage of IOP reduction and the 
mean IOP reduction throughout the visits was calculated.
Results
The baseline demographic characteristics are listed in 
Table 1.
In all, 32 eyes of 20 patients (8 unilateral and 12 bilateral) 
were enrolled in the study. Since both eyes had similar reaction 
in bilateral patients, one eye per patient was analyzed. Overall 
20 eyes were then included in the study. At the ﬁ  rst week
follow-up visit 4 eyes (20%) were found not respon-
dent to treatment: 3 eyes (15%) did not achieve an 
IOP reduction 3 mm Hg and 1 eye (5%) retained an 
IOP 22 mm Hg. At the sixth month follow-up visit, one 
eye (5%) failed because the IOP reduction was less than 3 
mm Hg from baseline.
The mean IOP had a prompt and signiﬁ  cant decrease 
(F = 45.91; p  0.01) that was maintained during the 12 
month follow-up as shown in Figure 1 and reported in 
Table 2.
Figure 2 shows the distribution of the percentage of eyes with 
IOP reduction  20%, between 20%–29% and 30% for the 15 
eyes that fulﬁ  lled our success criteria through the entire follow-
up. Ten of the 15 eyes (66.67%) had an IOP reduction 20%.
Table 1 Baseline demographic characteristics
Age (years)  61.7 ± 6.3
Sex  8 M; 12 F
Number of glaucoma  1 drop: 4 eyes (prostaglandins)
medications 
  2 drops: 18 eyes
    10 eyes beta-blockers
   and  prostaglandins
    2 eyes CAI and
   prostaglandins
    6 eyes beta-blockers
   and  CAI
  3 drops: 10 eyes
    8 eyes beta-blockers,
    CAI and prostaglandins
    2 eyes beta-blockers, α2-agonists,
   and  prostaglandins
Mean IOP (mm Hg)  24.7 ± 2.0
Central corneal   538.5 ± 11.53
thickness (μm)
Mean Defect (dB)  −7.4 ± 0.85
Abbreviations: CAI, carbonic anhydrase inhibitors; IOP, intraocular pressure.Clinical Ophthalmology 2008:2(2) 250
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The distribution, skewed to the left, indicates a small increase 
with time of eyes with IOP reduction 20% from baseline.
The mean ﬂ  are value at the Kowa FM 500 ﬂ  are-meter was 
not signiﬁ  cantly increased from the preoperative 10.12 ± 6.7 
fotons/msec throughout all the follow-up period (10.4 ± 5.3 
at the 12th month).
A marked increase in ﬂ  are occurred immediately after 
MDLT in the eye of a unilaterally treated patient with 
pigmentary glaucoma. His IOP rose to 34 mm Hg and was 
controlled with acetazolamide (Diamox 250 mg) for two 
days. On the third day, the IOP normalized and Diamox 
was discontinued. The IOP measurements taken during the 
two days on acetazolamide are not included in the analysis. 
No other patient had IOP or ﬂ  are spikes. The MDLT treatment 
was generally well tolerated with no pain and no annoying 
visible laser ﬂ  ashes. The total number of laser applications 
delivered at each eye over the inferior 180° ranged from a 
minimum of 70 to a maximum of 84 (mean 74.25 ± 3.8). 
Burning sensation was reported in two eyes (one patient) and 
heat sensations in four eyes (three patients). Treatments were 
completed with no complications. At the one year follow-up 
no patient had peripheral anterior synechiae. Visual acuity 
and visual ﬁ  eld were unchanged in all eyes.
Discussion
The objective of this prospective case series study was to 
evaluate the pressure lowering potential of MDLT in eyes 
with uncontrolled OAG over a clinically meaningful period. 
This is the ﬁ  rst published report on MDLT with a 12-month 
follow-up.
A previous controlled pilot study was presented by 
Ingvoldstad and colleagues (2005) at the 2005 ARVO meet-
ing. They compared the response to ALT and MDLT during 
a three-month follow-up period. These investigators reported 
similar, statistically signiﬁ  cant IOP reductions with the two 
techniques: 18.9% with ALT and 18.3% with MDLT.
We considered successful eyes only in our study because 
we operated on the eyes that failed. It was then impossible to 
compare the results obtained with surgery with those obtained 
by the trabeculoplasty method.
Figure 1 Mean intraocular pressure (IOP) at various time points up to 12 months (mean ± SE).
Table 2 Mean intraocular pressure (IOP) with standard deviation and mean IOP reduction from baseline at various time points up to 
12 months. The results of the paired t-test comparing the mean IOP at each time point to baseline are also shown
Baseline 
N = 20
3 Hours 
N = 20
1 Day 
N = 19
1 Week 
N = 16
1 Month 
N = 16
3 Months 
N = 16
6 Months 
N = 16
9 Months 
N = 15
12 Months 
N = 15
Mean IOP (mm Hg)
Standard deviation
25
2.1
20.1
2,4
19.6
1,2
18.7
1,8
18.9
1.7
19.2
1.3
19.2
1.4
19.3
1.7
19.5
1.7
Range 23–30 16–34 17–26 16–21 16–21 16–21 17–21 16–21 16–21
T 6.8 10.9 8.9 9.4 9.8 9.6 8.9 8.6
P 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001
Mean IOP 
reduction %   20.8% 20.9% 21.0% 23.8% `22.5% 22.2% 22.0% 21.3%
IOP vs time
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It is possible that we may have prematurely excluded the 
six nonresponders’ eyes and that some of them would have 
had late response to MDLT after the ﬁ  rst week. Positive late 
response to laser trabeculoplasty has been reported for ALT 
(Weireb et al 1983) and SLT (Latina and de Leon 2005), but 
a similar delayed effect could not be identiﬁ  ed in our study 
due to giving modiﬁ  ed therapy for these patients.
Due to our small number of eyes, it is not possible to 
identify individual patient characteristics and laser factors 
(ie, parameters for individual pigmentation, appropriate 
focussing, etc.) that might have inﬂ  uenced either a nonre-
sponse or a slower late response.
The micropulse laser energy delivered to the TM with 
our settings did not produce clinically visible morphologic 
changes at any time point. The lack of visible tissue changes 
constitutes a clinical challenge because, in the absence of 
a visible endpoint, the treatment relies on the surgeon’s skill; 
this could introduce variability. No acute histopathological 
changes and no damage to the TM beams were found in the 
histological specimens from an eye enucleated for choroi-
dal melanoma 24 hours after the MDLT treatment with our 
parameters (Midena 2005).
Except for one of our treated eyes, no postoperative 
ocular inﬂ  ammation was detected with the Kowa FM 500 
ﬂ  are-meter or clinical examination. An intraocular pressure 
spike and a ﬂ  are reaction occurred in one eye of a patient with 
pigmentary glaucoma. The IOP elevation was controlled in 
two days with systemic medication (acetazolamide). Con-
versely, IOP elevations after SLT in patients with pigmentary 
dispersion syndrome and with deeply pigmented trabecular 
meshwork can be a serious adverse event requiring ﬁ  ltering 
surgery (Latina et al 1998).
The mechanism of action of laser trabeculoplasty is 
poorly understood, but most recent hypotheses point toward 
a responsive cellular biochemical cascade (Parshley et al 
1996; Bradley et al 2000; Alvarado et al 2005). The threshold 
of laser-induced cellular effect to activate such a cascade 
is unknown. The fact that various laser trabeculoplasty 
techniques—applied with different lasers, endpoints, and 
protocols—have consistently produced comparable IOP-
lowering effects supports the hypothesis of a common cel-
lular mechanism. Such a cellular cascade could only occur in 
viable cells activated by a nonlethal thermal insult, directly 
applied, as in the case of MDLT, or derived from higher 
and lethal photothermal elevations produced by the laser in 
adjacent cells as in the case of ALT and of SLT. This would 
explain MDLT’s pressure lowering effect with subvisible 
laser applications that produce gentle photothermal effects 
that may sufﬁ  ce to activate the therapeutic cellular cascade 
without causing clinically visible damage nor intra- and 
post-operative side-effects.
The present pilot study has several limitations: a small 
number of patients, bilateral treatment in some patients, 
absence of a control group, and the fact that patients were 
on different preoperative medical treatments. We cannot rule 
out the possibility that, in some patients, some IOP lowering 
might have resulted from increased adherence to medical 
therapy after being entered in the study. This issue was 
addressed by Latina and colleagues (1998) in a pilot study, in 
which a very low confounding effect (0.9–2.1 mm Hg) sug-
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Figure 2 Distribution of the percentage of eyes with intraocular pressure (IOP) reduction from baseline 20%, between 20%–30%.Clinical Ophthalmology 2008:2(2) 252
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gested that the amount of IOP reduction from improved com-
pliance is not the predominant reason for response. We have 
no means to evaluate the impact of a hypothetical improved 
compliance, but the review of the last two years clinical his-
tory available in our clinic for all the patients entered in the 
study did not reveal clinically signiﬁ  cant IOP variations that 
could ﬂ  ag poor compliance to medical treatment.
Since most of the treatments were bilateral and pre-
operative medications were maintained during the follow-up, 
we can exclude any confounding effect due to the contra-
lateral action of drugs.
This preliminary report suggests that some IOP reduction 
can be achieved in a meaningful proportion of eyes without 
serious intra-operative and post-operative complications by 
MDLT. This laser procedure appears to be an alternative to 
ALT, DLT, or SLT. It is done with a laser device that can also 
be used for many other ophthalmic applications, thus reducing 
the economic burden of treatment. Whether a greater IOP reduc-
tion could be achieved by extending the treatment to the entire 
circumference of the angle or through the optimization of laser 
parameters, for example, by increasing the number and the duty 
cycle of the micropulses delivered for each application, remain 
to be investigated. Randomized clinical trials are warranted to 
compare MDLT with current IOP-lowering laser therapies such 
as ALT, SLT, or escalated antiglaucoma medications.
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